Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Hospital-acquired pneumonia is a common complication that continues to have a poor cure rate in some patients with intravenous therapy alone. Aerosolized antibiotics are theoretically attractive in an attempt to optimize lung concentrations of antibiotics. Limited data suggest that aerosolized aminoglycosides or colistin in addition to intravenous therapy results in good response rates in patients with multidrug-resistant organisms or nonresponding pneumonia. Adverse events can occur, especially with colistin. When used, care should be taken to properly compound and administer aerosolized antibiotics to ensure tolerability and good drug delivery.

Original languageEnglish (US)
Pages (from-to)993-1000
Number of pages8
JournalExpert Review of Anti-Infective Therapy
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Ventilator-Associated Pneumonia
Colistin
Anti-Bacterial Agents
Pneumonia
Aminoglycosides
Lung
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. / Wood, G Christopher.

In: Expert Review of Anti-Infective Therapy, Vol. 9, No. 11, 01.11.2011, p. 993-1000.

Research output: Contribution to journalReview article

@article{2c084ba5ea9e4524a9256712ebbe41f7,
title = "Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia",
abstract = "Hospital-acquired pneumonia is a common complication that continues to have a poor cure rate in some patients with intravenous therapy alone. Aerosolized antibiotics are theoretically attractive in an attempt to optimize lung concentrations of antibiotics. Limited data suggest that aerosolized aminoglycosides or colistin in addition to intravenous therapy results in good response rates in patients with multidrug-resistant organisms or nonresponding pneumonia. Adverse events can occur, especially with colistin. When used, care should be taken to properly compound and administer aerosolized antibiotics to ensure tolerability and good drug delivery.",
author = "Wood, {G Christopher}",
year = "2011",
month = "11",
day = "1",
doi = "10.1586/eri.11.126",
language = "English (US)",
volume = "9",
pages = "993--1000",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia

AU - Wood, G Christopher

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Hospital-acquired pneumonia is a common complication that continues to have a poor cure rate in some patients with intravenous therapy alone. Aerosolized antibiotics are theoretically attractive in an attempt to optimize lung concentrations of antibiotics. Limited data suggest that aerosolized aminoglycosides or colistin in addition to intravenous therapy results in good response rates in patients with multidrug-resistant organisms or nonresponding pneumonia. Adverse events can occur, especially with colistin. When used, care should be taken to properly compound and administer aerosolized antibiotics to ensure tolerability and good drug delivery.

AB - Hospital-acquired pneumonia is a common complication that continues to have a poor cure rate in some patients with intravenous therapy alone. Aerosolized antibiotics are theoretically attractive in an attempt to optimize lung concentrations of antibiotics. Limited data suggest that aerosolized aminoglycosides or colistin in addition to intravenous therapy results in good response rates in patients with multidrug-resistant organisms or nonresponding pneumonia. Adverse events can occur, especially with colistin. When used, care should be taken to properly compound and administer aerosolized antibiotics to ensure tolerability and good drug delivery.

UR - http://www.scopus.com/inward/record.url?scp=80155142495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155142495&partnerID=8YFLogxK

U2 - 10.1586/eri.11.126

DO - 10.1586/eri.11.126

M3 - Review article

VL - 9

SP - 993

EP - 1000

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 11

ER -